Physician profile
Paul Bedocs
NPI 1295714350
$7,520.49
in general payments reported to CMS, 2019-2025
38 companies · $1,937 in 2025
The $1,937 reported for 2025 was more than what 75% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $366 · 2020: $217 · 2021: $825 · 2022: $854 · 2023: $1,314 · 2024: $2,007 · 2025: $1,937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,155 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,154.80 |
| Education | $103.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,877.02 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Lilly USA, LLC | $980.40 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $590.92 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $520.37 | 2019-2025 | |
| Ucb, INC. | $422.66 | 2019-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $320.64 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $299.41 | 2021-2025 | Odomzo, Blu-U, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $289.85 | 2020-2025 | Libtayo, Dupixent |
| Amgen INC. | $286.25 | 2020-2025 | Otezla, Otezla, Enbrel |
| Pfizer INC. | $238.93 | 2021-2025 | |
| Organon LLC | $218.05 | 2025 | Vtama, Hadlima |
| Dermavant Sciences, INC. | $201.12 | 2022-2024 | Vtama |
| Genzyme Corporation | $181.84 | 2019-2025 | |
| Incyte Corporation | $155.56 | 2021-2024 | Opzelura |
| Leo Pharma INC. | $147.45 | 2023-2025 | Adbry, Anzupgo |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $144.27 | 2019-2025 | Aklief, Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.79 | 2022-2024 | Spevigo, Cyltezo |
| Convatec INC. | $81.68 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $39.33 | 2023-2024 | |
| Dermira, INC. | $35.17 | 2019-2020 | |
| Lnhc, INC | $32.13 | 2025 | Zelsuvmi |
| Strata Skin Sciences, INC. | $30.18 | 2024-2025 | Xtrac |
| Biofrontera INC. | $28.20 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Mimedx Group, INC. | $26.20 | 2025 | |
| Chiesi USA, INC. | $25.99 | 2024 | Filsuvez |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.52 | 2020-2021 | |
| Allergan, INC. | $24.09 | 2021 | |
| Celgene Corporation | $23.48 | 2019 | |
| Mylan Institutional INC. | $20.57 | 2023 | |
| Organogenesis INC. | $19.94 | 2025 | Cygnus Dual |
| Almirall LLC | $18.91 | 2023 | Seysara |
| Arcutis Biotherapeutics, INC. | $18.61 | 2025 | Zoryve |
| Kyowa Kirin, INC. | $17.70 | 2024 | Poteligeo |
| Kerecis Limited | $17.64 | 2022 | |
| Cipher Pharmaceuticals US LLC | $16.63 | 2025 | Natroba, Spinosad |
| Verrica Pharmaceuticals INC. | $15.12 | 2024 | Ycanth |
| Genentech USA, INC. | $14.12 | 2024 | Erivedge |
| Fresenius Kabi USA, LLC | $12.75 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Bedocs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.